| Productname |
YKL-40 for Rheumatology and Oncology (Quidel®) |
|
Human Cartilage Glycoprotein 39 |
| Cat-No. |
8020 |
|
4821 YKL-40 Control Set of 3 times 0.5 ml (3 levels)
Average: 45, 168, 240 ng/ml |
| Range |
20 - 300 ng/ml |
| Sensitivity |
LOD: 5.4 ng/ml; LLOQ: 15.6 ng/ml |
| Incubation time |
3 hours |
| Sample volume |
20 µl |
| Sample type |
Serum, synovial fluid, plasma, cell culture, CSF. |
| Sample preparation |
Serum stable for 3 hours at RT, plasma stable for 8 hours at RT.
For longer storage, freeze specimens at -20 °C or below. |
| Reference values |
| |
ng/ml |
| Women (< 60 years) |
25 - 93 |
| Men (< 60 years) |
24 - 125 |
|
| Species |
Human, baboon, rhesus macaque, cynomolgus macaque |
| Tests |
96 Tests |
| Method |
ELISA |
| Product informations |
- Kit Instructions (pdf-File 177 kb)
- Cross-reaction all species (pdf-File 71 kb)
- Datasheet (pdf-File 647 kb)
- Bone & Cartilage Metabolism (pdf-File 2,480 kb)
- Cartilage Monograph (pdf-File 512 kb)
- Information (pdf-File 646 kb)
|
| Intended use |
YKL-40 is a 40-kDa heparin-binding glycoprotein. Increased serum YKL-40 levels were found in patients with rheumatoid arthritis and osteoarthritis, inflammatory intestinal diseases, heavy bacterial infections and liver fibrosis.
Further areas:
• Oncology
• Asthma
Literature overview available for the different clinical application. |
| Keywords product |
YKL-40, ELISA, Cartilage Synthesis, Cartilage Glycoprotein-39, Rheumatoid Arthritis, Fibrosis, Osteoarthritis, Cancer, Asthma, Cartilagemarker, Therapy efficiency |
Back to overview print view
